Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 1,869,498 shares, a decrease of 24.3% from the October 14th total of 2,470,629 shares. Approximately 10.6% of the company’s stock are short sold. Based on an average trading volume of 1,225,724 shares, the days-to-cover ratio is presently 1.5 days.

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.05 on Thursday. The stock’s market capitalization is $142.91 million. Aurinia Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $5.69. The firm’s 50-day moving average is $3.50 and its 200 day moving average is $2.88.

A number of institutional investors have recently made changes to their positions in AUPH. Redmile Group LLC raised its position in shares of Aurinia Pharmaceuticals by 560.4% in the third quarter. Redmile Group LLC now owns 187,610 shares of the company’s stock valued at $565,000 after buying an additional 159,200 shares in the last quarter. KCG Holdings Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at approximately $153,000. SG Americas Securities LLC purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at approximately $1,123,000. Creative Planning purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at approximately $181,000. Finally, Lombard Odier Asset Management USA Corp raised its position in shares of Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock valued at $283,000 after buying an additional 2,813 shares in the last quarter. 19.34% of the stock is owned by institutional investors and hedge funds.

AUPH has been the subject of several recent analyst reports. FBR & Co set a $9.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 12th. Leerink Swann restated an “outperform” rating on shares of Aurinia Pharmaceuticals in a research report on Tuesday, August 16th. HC Wainwright increased their price target on shares of Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, August 17th. Mackie restated a “buy” rating and set a $8.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 2nd. Finally, Canaccord Genuity restated a “buy” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Saturday, October 8th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Aurinia Pharmaceuticals has a consensus rating of “Buy” and an average target price of $7.79.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

5 Day Chart for NASDAQ:AUPH

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.